November 17th, 2026Don't Miss a Beat: How Prediction Markets Could Threaten Clinical Trial IntegrityAnkeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.Read more
November 16th, 2026FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCMAficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.Read more
November 10th, 2026Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial ScienceLp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.Read more
November 9th, 2026The HCPFive: Top News for Healthcare Providers from the Week of 11/1Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.Read more
November 9th, 2026Asundexian Receives FDA Approval for Secondary Stroke PreventionThe FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.Read more
November 18th, 2026What FAERS Anaphylaxis Data Can and Cannot Tell Biologic Prescribers In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next. Read more
November 18th, 2026Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics. Read more
November 18th, 2026RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPFPooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.Read more